2 weeks Ago By ABMN Staff
Marathon Capital Management increased its holdings in Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX – Free Report ) by 1.6% in the 2nd quarter, Holdings Channel reports.
The institutional investor owned 175,220 shares of the company’s stock after purchasing an additional 2,675 shares during the period. Marathon Capital Management’s holdings in Recursion Pharmaceuticals were worth $1,314,000 as of its most recent filing with the Securities and Exchange Commission. Other institutional investors and hedge funds also recently bought and sold shares of the company.
Employees Retirement System of Texas boosted its holdings in Recursion Pharmaceuticals by 13.4% in the 2nd quarter. Employees Retirement System of Texas now owns 50,351 shares of the company’s stock valued at $378,000 after purchasing an additional 5,953 shares during the period.
Xponance Inc. bought a new position in Recursion Pharmaceuticals in the 2nd quarter valued at $98,000. Ensign Peak Advisors Inc boosted its holdings in Recursion Pharmaceuticals by 2.
5% in the 2nd quarter. Ensign Peak Advisors Inc now owns 408,986 shares of the company’s stock valued at $3,067,000 after purchasing an additional 10,050 shares during the period. Public Employees Retirement Association of Colorado bought a new position in Recursion Pharmaceuticals in the 2nd quarter valued at $129,000.
Finally, Benjamin F. Edwards & Company Inc. boosted its holdings in Recursion Pharmaceuticals by 6,439.
6% in the 2nd quarter. Benjamin F. Edwards & Company Inc.
now owns 169,900 shares of the company’s stock valued at $1,274,000 after purchasing an additional 167,302 shares during the period. 89.06% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth Several research analysts have commented on RXRX shares. Jefferies Financial Group cut their price target on shares of Recursion Pharmaceuticals from $8.00 to $6.
00 and set a “hold” rating for the company in a report on Tuesday, September 3rd. Leerink Partners lowered their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.
00 and set a “market perform” rating on the stock in a research report on Tuesday, September 3rd. KeyCorp lowered their price objective on shares of Recursion Pharmaceuticals from $16.00 to $12.
00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Finally, Needham & Company LLC lowered their price objective on shares of Recursion Pharmaceuticals from $16.00 to $11.
00 and set a “buy” rating on the stock in a research report on Wednesday, September 4th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.
com, Recursion Pharmaceuticals presently has an average rating of “Hold” and an average target price of $9.40. Recursion Pharmaceuticals Price Performance Shares of NASDAQ:RXRX opened at $7.
17 on Friday. The stock has a market cap of $1.70 billion, a PE ratio of -4.
48 and a beta of 0.82. The company’s fifty day moving average is $7.
04 and its 200 day moving average is $8.25. Recursion Pharmaceuticals, Inc.
has a 52 week low of $4.97 and a 52 week high of $15.74.
The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.
04. Recursion Pharmaceuticals ( NASDAQ:RXRX – Get Free Report ) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.
40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05).
Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%.
The firm had revenue of $14.42 million during the quarter, compared to analysts’ expectations of $11.96 million.
During the same quarter in the previous year, the firm posted ($0.38) EPS. Recursion Pharmaceuticals’s revenue was up 30.
9% compared to the same quarter last year. Research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.
58 earnings per share for the current year. Insider Buying and Selling at Recursion Pharmaceuticals In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $7.
32, for a total value of $83,792.04. Following the transaction, the director now owns 7,167,110 shares in the company, valued at $52,463,245.
20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink . In other news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, July 9th.
The shares were sold at an average price of $7.32, for a total transaction of $83,792.04.
Following the sale, the director now owns 7,167,110 shares of the company’s stock, valued at approximately $52,463,245.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website .
Also, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $8.13, for a total transaction of $48,780.
00. Following the sale, the chief operating officer now directly owns 535,457 shares in the company, valued at approximately $4,353,265.41.
The disclosure for this sale can be found here . Over the last quarter, insiders have sold 225,682 shares of company stock worth $1,590,044. 15.
75% of the stock is currently owned by company insiders. Recursion Pharmaceuticals Company Profile ( Free Report ) Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Read More Want to see what other hedge funds are holding RXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Recursion Pharmaceuticals, Inc. ( NASDAQ:RXRX – Free Report ).
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
